Formycon Wins Endorsement For Second EU Lucentis Rival

CHMP Positive Opinion For Ranivisio Sets Up Approval For Ranibizumab Biosimilar

Formycon has seen its FYB201 ranibizumab biosimilar rival to Lucentis recommended for approval by the EMA’s CHMP, under the name Ranivisio. Teva has rights to market the product in Europe and is preparing for launch.

EU Flag Eye Close-Up
Formycon’s biosimilar is the second approved EU rival to Lucentis • Source: Shutterstock

Formycon and its licensing partner Bioeq have celebrated receiving a positive opinion from the Committee for Medicinal Products for Human Use within the European Medicines Agency, recommending granting a pan-European marketing authorization for the firms’ FYB201 biosimilar rival to Lucentis (ranibizumab) under the name Ranivisio.

The positive opinion represents the second biosimilar version of Lucentis to be endorsed by the EMA, following Samsung Bioepis receiving...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.